.After a few years in biotech, Mike Quigley, Ph.D., is coming back to the pharma layer, taking up the best science area at Sanofi.Quigley will begin Sept. 30 as the French Big Pharma’s main medical officer and also global chief of research, Sanofi told Ferocious Biotech in an emailed statement.Quigley is changing Frank Nestle, M.D., that left behind Sanofi this spring in the middle of an international overhaul of the business’s R&D unit. Nestle, who invested 8 years with the pharma, dove over to Deerfield Management, where he currently functions as a companion on the therapies staff and also CEO of the organization’s curative discovery and also advancement functions.
Quigley will certainly sign up with Sanofi from a San Francisco-based biotech that’s in stealth, according to his LinkedIn profile. He is actually currently detailed as the provider’s founder, head of state as well as chief executive officer.Considering that August 2021, Quigley has actually worked as a venture partner at SV Health and wellness Investors, a health care fund supervisor with existing expenditures in biotechs such as BioAge, Cerevance, Dualitas Rehabs as well as Nimbus Rehabs, to name a few. Quigley formerly stored the best place at Dualitas, a biotech that stays in secrecy, depending on to STAT.The soon-to-be Sanofi forerunner also formerly helmed Therini Biography, an immunotherapy biotech functioning to create treatments for neurodegenerative ailments driven by vascular dysfunction.Before investing the final handful of years in biotech, Quigley possesses an even longer record in Big Pharma, most just recently functioning as Gilead’s elderly bad habit head of state of analysis the field of biology till the summer season of 2021.
Before that, he clocked in greater than four years across various leadership parts at Bristol Myers Squibb and also functioned as a clinical supervisor at Johnson & Johnson’s Janssen arm just before that.Sanofi said Quigley’s mission in his brand new duty would certainly be actually to “optimize our chance of effectiveness via optimum collaborations throughout our organization and also beyond, delivering best-in-class development along with establishing and sourcing brand-new industry-leading talent along with a commitment to variety,” depending on to an inner memo acquired by STAT.